Hepatocellular carcinoma (HCC) is one of the most common potentially lethal human
malignancies worldwide. Sorafenib, a tyrosine kinase inhibitor, was recently approved by the …

BACKGROUND & AIMS: Recently, we reported that sorafenib sensitizes hepatocellular
carcinoma (HCC) cells to TRAIL through the inhibition of signal transducer and activator of …

Purpose: Recombinant tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is a
promising antitumor agent. However, many hepatocellular carcinoma (HCC) cells show …

The multiple kinase inhibitor dovitinib is currently under clinical investigation for hepatocellular
carcinoma (HCC). Here, we investigated the mechanistic basis for the effects of dovitinib …

Purpose: Here, we aim to investigate the molecular mechanism of regorafenib and verify the
potential druggable target for the treatment of hepatocellular carcinoma (HCC). …

Hepatocellular carcinoma (HCC) is the most common liver cancer and the third-leading
cause of cancer death worldwide. Nilotinib is an orally available receptor tyrosine kinase …

Signal transducer and activator of transcription 3 (STAT3) had been involved in liver
fibrogenesis. We aimed to explore the antifibrotic activities of sorafenib and its derivative SC-1 (…

Previously, we demonstrated that the multiple kinase inhibitor sorafenib mediates the repression
of phospho-STAT3 in hepatocellular carcinoma cells. In this study, we used this kinase-…

Selection of the best tumor antigen is critical for the therapeutic success of chimeric antigen
receptor (CAR) T cells in hematologic malignancies and solid tumors. The anaplastic …

Introduction Signal transducers and activators of transcription 3 (STAT3) signaling is
constitutively activated in various cancers including breast cancer and has emerged as a novel …